Stocktoria
Serina Therapeutics, Inc. SER
NYSE American · XASE · stock · Pharmaceutical Preparations · website · IPO 2018-11-29
Serina Therapeutics, Inc. financials (annual, from 10-K)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $130,000 | $56,000 | $3.2M | $34,000 | $144,000 | $361,000 | $1.7M | $1.4M | $1.4M |
| Gross profit | — | — | $102,000 | $21,000 | $125,000 | $335,000 | $1.5M | $1.0M | $1.2M |
| R&D expense | $13.2M | $7.5M | $2.4M | $1.0M | $1.5M | $3.7M | $5.9M | $5.8M | $5.8M |
| Operating income | -$24.0M | -$17.0M | -$3.1M | -$7.0M | -$7.9M | -$10.1M | -$12.6M | -$11.2M | -$6.7M |
| Interest expense | — | — | $4.9M | $3.3M | $1.1M | — | — | — | — |
| Income tax | $18,000 | $0 | $0 | — | — | -$150,000 | $148,000 | — | — |
| Net income | -$19.2M | -$11.1M | $5.3M | -$10.5M | -$8.7M | -$10.9M | -$12.2M | -$7.5M | -$6.6M |
| EPS (diluted) | $-1.91 | $-1.51 | $0.73 | $-9.70 | — | — | — | — | — |
| Operating cash flow | -$18.0M | -$17.1M | -$2.5M | -$5.9M | -$7.9M | -$8.0M | -$10.2M | -$8.0M | -$6.3M |
| Free cash flow | -$18.0M | -$17.2M | — | — | — | -$8.0M | -$10.8M | -$8.0M | -$6.3M |
| Cash & equivalents | $3.1M | $3.7M | $7.6M | $645,000 | $584,000 | $527,000 | $2.4M | $6.7M | $7.4M |
| Total assets | $7.0M | $6.7M | $9.0M | $3.2M | $3.2M | $3.9M | $7.4M | $10.7M | $9.6M |
| Total liabilities | $7.0M | $6.2M | $4.9M | $20.6M | $15.0M | $9.3M | $4.8M | $2.4M | $1.3M |
| Shareholders' equity | -$37,000 | $641,000 | -$32.3M | -$37.8M | -$11.9M | -$5.4M | $2.6M | $8.2M | $8.3M |
Growth · year-over-year · Revenue CAGR -25.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +132.1% | -98.2% | +9173.5% | -76.4% | -60.1% | -79.1% | +23.8% | -0.6% | — |
| Net income growth | — | -311.4% | — | — | — | — | — | — | — |
| EPS growth | — | -306.8% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001708599 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.